Sagent Pharma, a US company specializing in injectible drugs, will sell its Sagent (China) Pharmaceuticals subsidiary, booking a loss of as much as $50 million. In 2013, Sagent took its China JV in-house, paying $25 million to partner Chegdu Kanghong Pharma for its 50% stake. In November, during the company’s 2015 Q3 earnings call, Sagent said the China facility was running at a net loss of $1 million per month. Fixing the problem, Sagent declared, would cost too much and take too long.
